Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 9, 2014, Pages 1933-1941

  Cai, Wenzhi ^a   Tao, Jie ^a   Zhang, Xiaolin ^a   Tian, Xiaoxiang ^a   Liu, Tengfei ^a   Feng, Xueyao ^a   Bai, Jing ^a   Yan, Chenghui ^a   Han, Yaling ^a  

^a Cardiovascular Research Institute Department of Cardiology Shenyang Northern Hospital ^*  (China)

Author keywords

atherosclerosis; coronary artery disease; monocytes; polymorphism, single nucleotide

Indexed keywords

ATORVASTATIN; CHEMOKINE; CHEMOKINE RECEPTOR CCR7; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; NEUTRALIZING ANTIBODY; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ALLELISM; ARTICLE; ATHEROGENESIS; CELL ADHESION ASSAY; CELL MIGRATION; CHINESE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; GENETIC VARIABILITY; GENOTYPE; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UMBILICAL VEIN ENDOTHELIAL CELL;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; MONOCYTES; POLYMORPHISM; SINGLE NUCLEOTIDE;

AGED; ALLELES; CELL ADHESION; CHEMOKINE CCL19; CHEMOKINE CCL21; CHEMOTAXIS, LEUKOCYTE; CHINA; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; ETHNIC GROUPS; FEMALE; GENOTYPE; HEPTANOIC ACIDS; HOMEOSTASIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; PLAQUE, ATHEROSCLEROTIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; RECEPTORS, CCR7; SIGNAL TRANSDUCTION;

EID: 84907963279     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.303081     Document Type: Article

References (30)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
2. Koenen RR, Weber C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol Med. 2011;3:713-725.
3. Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature. 1998;391:799-803.
4. Weyand CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid synovitis. Ann N Y Acad Sci. 2003;987:140-149.
5. Damås JK, Smith C, Øie E, et al. Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol. 2007;27:614-620.
6. Nickel T, Pfeiler S, Summo C, Kopp R, Meimarakis G, Sicic Z, Lambert M, Lackermair K, David R, Beiras-Fernandez A, Kaczmarek I, Weis M. oxLDL downregulates the dendritic cell homing factors CCR7 and CCL21. Mediators Inflamm. 2012;2012:320953.
7. Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109(21 suppl 1):II18-II26.
8. Côté SC, Pasvanis S, Bounou S, Dumais N. CCR7-specific migration to CCL19 and CCL21 is induced by PGE(2) stimulation in human monocytes: Involvement of EP(2)/EP(4) receptors activation. Mol Immunol. 2009;46:2682-2693.
9. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410-1422.
10. Luchtefeld M, Grothusen C, Gagalick A, Jagavelu K, Schuett H, Tietge UJ, Pabst O, Grote K, Drexler H, Förster R, Schieffer B. Chemokine receptor 7 knockout attenuates atherosclerotic plaque development. Circulation. 2010;122:1621-1628.
11. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher EA. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoEdeficient mice. Proc Natl Acad Sci U S A. 2006;103:3781-3786.
12. Wan W, Lionakis MS, Liu Q, Roffê E, Murphy PM. Genetic deletion of chemokine receptor Ccr7 exacerbates atherogenesis in ApoE-deficient mice. Cardiovasc Res. 2013;97:580-588.
13. Recinos A III, LeJeune WS, Sun H, Lee CY, Tieu BC, Lu M, Hou T, Boldogh I, Tilton RG, Brasier AR. Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis. 2007;194:125-133.
14. Shah R, Hinkle CC, Ferguson JF, Mehta NN, Li M, Qu L, Lu Y, Putt ME, Ahima RS, Reilly MP. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes. 2011;60:1512-1518.
15. Zhou J, Tang PC, Qin L, Gayed PM, Li W, Skokos EA, Kyriakides TR, Pober JS, Tellides G. CXCR3-dependent accumulation and activation of perivascular macrophages is necessary for homeostatic arterial remodeling to hemodynamic stresses. J Exp Med. 2010;207:1951-1966.
16. Cybulsky MI, Lichtman AH, Hajra L, Iiyama K. Leukocyte adhesion molecules in atherogenesis. Clin Chim Acta. 1999;286:207-218.
17. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol. 2004;13:125-138.
18. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol. 2000;71:1554-1560.
19. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-1361.
20. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17:179-188.
21. Pussinen PJ, Tuomisto K, Jousilahti P, Havulinna AS, Sundvall J, Salomaa V. Endotoxemia, immune response to periodontal pathogens, and systemic inflammation associate with incident cardiovascular disease events. Arterioscler Thromb Vasc Biol. 2007;27:1433-1439.
22. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, Salmona M. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol. 2001;21:1327-1332.
23. Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S, Mach F. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis. 2006;188:51-58.
24. Elton TS, Sansom SE, Martin MM. Cardiovascular disease, single nucleotide polymorphisms; and the renin angiotensin system: is there a microRNA connection? Int J Hypertens. 2010;1:20948563.
25. Muiños-Gimeno M, Guidi M, Kagerbauer B, Martín-Santos R, Navinés R, Alonso P, Menchón JM, Gratacòs M, Estivill X, Espinosa-Parrilla Y. Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. Hum Mutat. 2009;30:1062-1071.
26. Meijer CA, Le Haen PA, van Dijk RA, Hira M, Hamming JF, van Bockel JH, Lindeman JH. Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study. Clin Sci (Lond). 2012;122:421-428.
27. Pagani F, Baralle FE. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet. 2004;5:389-396.
28. Silva GA, Santos MP, Mota-Passos I, Boechat AL, Malheiro A, Naveca FG, de Paula L. IFN-? +875 microsatellite polymorphism as a potential protection marker for leprosy patients from Amazonas state, Brazil. Cytokine. 2012;60:493-497.
29. Gu X, Wang H, Wang A, Dou T, Qi P, Ji Q, Li H, Gao C. An intronic polymorphism rs2237062 in the CXCL14 gene influences HBVrelated HCC progression in Chinese population. Mol Biol Rep. 2012;39:797-803.
30. Shannon LA, McBurney TM, Wells MA, Roth ME, Calloway PA, Bill CA, Islam S, Vines CM. CCR7/CCL19 controls expression of EDG-1 in T cells. J Biol Chem. 2012;287:11656-11664.